289 related articles for article (PubMed ID: 26983575)
21. Unraveling galectin-1 as a novel therapeutic target for cancer.
Astorgues-Xerri L; Riveiro ME; Tijeras-Raballand A; Serova M; Neuzillet C; Albert S; Raymond E; Faivre S
Cancer Treat Rev; 2014 Mar; 40(2):307-19. PubMed ID: 23953240
[TBL] [Abstract][Full Text] [Related]
22. Mapping the Pathways of Resistance to Targeted Therapies.
Wood KC
Cancer Res; 2015 Oct; 75(20):4247-51. PubMed ID: 26392071
[TBL] [Abstract][Full Text] [Related]
23. Terpenoids as anti-colon cancer agents - A comprehensive review on its mechanistic perspectives.
Sharma SH; Thulasingam S; Nagarajan S
Eur J Pharmacol; 2017 Jan; 795():169-178. PubMed ID: 27940056
[TBL] [Abstract][Full Text] [Related]
24. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.
Rohwer N; Cramer T
Drug Resist Updat; 2011 Jun; 14(3):191-201. PubMed ID: 21466972
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of acquired resistance to targeted cancer therapies.
Lackner MR; Wilson TR; Settleman J
Future Oncol; 2012 Aug; 8(8):999-1014. PubMed ID: 22894672
[TBL] [Abstract][Full Text] [Related]
26. Rational targeting of Notch signaling in cancer.
Rizzo P; Osipo C; Foreman K; Golde T; Osborne B; Miele L
Oncogene; 2008 Sep; 27(38):5124-31. PubMed ID: 18758481
[TBL] [Abstract][Full Text] [Related]
27. Cancer cells acquire resistance to anticancer drugs: an update.
Lu HP; Chao CC
Biomed J; 2012; 35(6):464-72. PubMed ID: 23442359
[TBL] [Abstract][Full Text] [Related]
28. Redox-sensitive signaling factors as a novel molecular targets for cancer therapy.
Pennington JD; Wang TJ; Nguyen P; Sun L; Bisht K; Smart D; Gius D
Drug Resist Updat; 2005 Oct; 8(5):322-30. PubMed ID: 16230045
[TBL] [Abstract][Full Text] [Related]
29. Redox-inactive analogue of tocotrienol as a potential anti-cancer agent.
Yano T; Sato A; Sekine M; Virgona N; Ota M
Anticancer Agents Med Chem; 2013 Mar; 13(3):496-501. PubMed ID: 22721395
[TBL] [Abstract][Full Text] [Related]
30. Modulation of cell sensitivity to antitumor agents by targeting survival pathways.
Perego P; Cossa G; Zuco V; Zunino F
Biochem Pharmacol; 2010 Nov; 80(10):1459-65. PubMed ID: 20688050
[TBL] [Abstract][Full Text] [Related]
31. Potential Effects of Geraniol on Cancer and Inflammation-Related Diseases: A Review of the Recent Research Findings.
Ben Ammar R
Molecules; 2023 Apr; 28(9):. PubMed ID: 37175079
[TBL] [Abstract][Full Text] [Related]
32. Concentration-dependent increase of murine P388 and B16 population doubling time by the acyclic monoterpene geraniol.
Shoff SM; Grummer M; Yatvin MB; Elson CE
Cancer Res; 1991 Jan; 51(1):37-42. PubMed ID: 1988098
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of 1% geraniol (Fulltec) as a tick repellent.
Khallaayoune K; Biron JM; Chaoui A; Duvallet G
Parasite; 2009 Sep; 16(3):223-6. PubMed ID: 19839268
[TBL] [Abstract][Full Text] [Related]
34. Preclinical Evidence on the Anticancer Properties of Food Peptides.
Rajendran SR; Ejike CE; Gong M; Hannah W; Udenigwe CC
Protein Pept Lett; 2017; 24(2):126-136. PubMed ID: 27538700
[TBL] [Abstract][Full Text] [Related]
35. Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways.
Li N; Zhang CX; Wang XX; Zhang L; Ma X; Zhou J; Ju RJ; Li XY; Zhao WY; Lu WL
Biomaterials; 2013 Apr; 34(13):3366-80. PubMed ID: 23410681
[TBL] [Abstract][Full Text] [Related]
36. Geraniol and beta-ionone inhibit proliferation, cell cycle progression, and cyclin-dependent kinase 2 activity in MCF-7 breast cancer cells independent of effects on HMG-CoA reductase activity.
Duncan RE; Lau D; El-Sohemy A; Archer MC
Biochem Pharmacol; 2004 Nov; 68(9):1739-47. PubMed ID: 15450939
[TBL] [Abstract][Full Text] [Related]
37. Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways.
Leon G; MacDonagh L; Finn SP; Cuffe S; Barr MP
Pharmacol Ther; 2016 Feb; 158():71-90. PubMed ID: 26706243
[TBL] [Abstract][Full Text] [Related]
38. Targeted manipulation of apoptosis in cancer treatment.
Call JA; Eckhardt SG; Camidge DR
Lancet Oncol; 2008 Oct; 9(10):1002-11. PubMed ID: 18760670
[TBL] [Abstract][Full Text] [Related]
39. [Drug resistance mediated by survival- and growth-promoting signaling pathways].
Fujita N
Gan To Kagaku Ryoho; 2009 Apr; 36(4):567-71. PubMed ID: 19381028
[TBL] [Abstract][Full Text] [Related]
40. Geraniol and simvastatin show a synergistic effect on a human hepatocarcinoma cell line.
Polo MP; Crespo R; de Bravo MG
Cell Biochem Funct; 2011 Aug; 29(6):452-8. PubMed ID: 21735455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
